Report Overview
The global gastroretentive drug delivery systems outsourcing market size was valued at USD 1.33 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.99 % from 2023 to 2030. The increased outsourcing demand and rising disease burden throughout the globe are major driving factors for market growth. Advanced formulation technologies are anticipated to create growth opportunities for the market in the coming years. The industry is experiencing advances in formulation technologies, allowing the creation of more sophisticated and personalized gastroretentive drug delivery systems (GRDDS). This includes advancements in polymer science, controlled-release techniques, and bioavailability improvement.
Furthermore, the numerous benefits associated with the use of GRDDS are also expected to drive market growth. Gastroretentive drug delivery systems offer various advantages, such as enhancing patient adherence by reducing the dosing frequency, improving the efficacy of short half-life drugs, enabling targeted drug delivery, sustaining controlled release within the stomach, prolonging drug presence at absorption sites, increasing drug bioavailability in the gastrointestinal tract, and preventing the sudden release of doses.
Moreover, the increasing prevalence of gastric-related diseases such as peptic ulcer and gastric ulcer are expected to drive overall market growth. For instance, as per the National Institutes of Health, each year, peptic ulcer disease (PUD) impacts approximately four million people globally, with an estimated lifetime prevalence ranging from 5% to 10% within the general population.Gastroretentive drug delivery systems are formulated to have prolonged gastric retention times. This design facilitates direct interaction with the ulcer site, resulting in elevated drug concentrations, specifically at the affected region.
Dosage Form Insights
The tablets segment dominated the gastroretentive drug delivery systems outsourcing market with a revenue share of over 38% in 2022.The increased focus of manufacturers on creating gastroretentive tablets is expected to drive segment growth. Gastroretentive tablets provide regulated and sustained medication release over a long period of time. This regulated release can result in more constant medicine blood levels, lowering the frequency of dosage and improving patient convenience. Gastroretentive tablets can improve the bioavailability of some medications, particularly those with low solubility or permeability.
On the other hand, the capsule segment is expected to witness significant CAGR in the coming years. Multiple players in the gastroretentive drug delivery system market are developing capsule-based gastroretentive drugs owing to their increased efficiency. These drugs offer various advantages, such asease of swallowing and customizable release profiles. Capsules with specialized coatings, materials, and formulation procedures can be designed to create controlled and prolonged medication release features.This modification enables medication release kinetics to be tailored to therapeutic demands.
Regional Insights
In 2022, North America dominated the market with a revenue share of over 47% and is expected to grow rapidly during the forecast period. The advanced pharmaceutical industry, the high prevalence of cancer, and increasing initiatives by key market participants contribute largely to North America’s leading market share in 2022. Moreover, the favorable regulatory environment in the region is expected to boost regional growth. North America's pharmaceutical and biotechnology sectors are subject to stringent regulatory requirements, resulting in the creation of high-quality, well-regulated outsourcing services. Clients looking for outsourcing partners frequently prioritize regions with robust regulatory frameworks to assure safety and compliance.
The Asia Pacific region is expected to expand with a CAGR of around 7.4% during the forecast period. The growth of this regional market has been fueled by the presence of a large patient pool. Moreover, increasing government support for the pharmaceutical industry is also expected to propel market growth. Some Asian countries have developed regulations and incentives to encourage pharmaceutical research and development, including drug delivery technology. These efforts have the potential to attract both domestic and international companies seeking outsourcing partners.
Key Companies & Market Share Insights
Key companies in the market are undertaking various strategic initiatives such as partnerships, new service launches, mergers, and acquisitions to strengthen their market position. For instance, in August 2022, Catalent announced an agreement to acquire Metrics Contract Services for USD 475 million in order to expand its high-potential capabilities, as well as its oral development and manufacturing capacity.This development is expected to boost Catalent's expertise in integrated oral solid formulation research, production, and packaging, allowing clients to accelerate and simplify their programs. Some of the notable players in the global gastroretentive drug delivery systems outsourcing market include:
Catalent
Lonza
Evonik
Colorcon
Quotient Sciences
Aptar Pharma
Aenova Group
Evotec
Vectura Group Ltd.
Ashland